Best Life Sciences Companies in Nanjing, China
The 40 best Life Sciences companies in Nanjing, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: IASO BIO.
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Nanjing
| # | Company | Last round | Disclosed funding | Stage | Founder | Tech stack | Employees | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CamRay Photonics Manufacturer of systems and technologies for X-ray imaging | — | — | Deadpooled | Yan Zhang Founder & CEO | — | — | — | — |
| 2 | CareAI Developer of AI and liquid biopsy based cancer detection | — | — | Deadpooled | Feng Xueyang CEO | — | — | — | — |
| 3 | Genmedic Developer of cell-based therapy for genetic disorders | — | — | Unfunded | Tung Wen-chi Co-Founder | — | — | — | — |
| 4 | Heading (Nanjing) Pharmtechnologies Provider of services for commercial production of APIs and intermediates | — | — | Funding Raised | Zhang Wenqi CEO | — | — | — | — |
| 5 | Jiangsu Kang Pharmaceutical Developer of transdermal delivery system for drug delivery | — | — | Funding Raised | — | — | 74 | — | — |
| 6 | Jiangsu Subo Biomedical Provider services and products for gene sequencing based research and testing for forensic and others analysis | — | — | Funding Raised | — | — | 261 | — | — |
| 7 | Juvensis Therapeutics Developer of gene therapy drugs to treat heart failure | — | — | Funding Raised | Xiao Xu Founder & CEO | — | — | — | — |
| 8 | KAEDI Developer of CAR-T cell therapies for cancer treatment | — | — | Unfunded | Paul Dai Co-Founder & CEO | — | — | — | — |
Top 12 Life Sciences companies in Nanjing
#1
Public · Nanjing, Jiangsu · founded 2009 · 7 employees$145.2Mraised▾
Developer of small molecule therapeutics for the treatment of cancer. The company's product line include Senaparib is a PARP inhibitor for ovarian cancer maintenance therapy and small cell lung cancer, meeting primary endpoints in the FLAMES study for superior efficacy and safety. Other assets include WEE1 inhibitor IMP7068, ATR inhibitor IMP9064, and PARP1-selective inhibitor IMP1734 (collaborating with Eikon Therapeutics), alongside additional DDR inhibitors.
- Nov 2024Series D$34.5M
- Apr 2024Series D$55.2M
- Mar 2022Series D—
- Nov 2020Series C$50M
#2
Seed · Nanjing, Jiangsu · founded 2021$13.6Mraised▾
Developer of novel analgesic drugs targeting Nav1.8 and Nav1.7 ion channels. This company focuses on the research and development of innovative pain treatment medications. The company's research centers on two sodium ion channels, Nav1.8 and Nav1.7, which are closely linked to the body's pain perception. A team with extensive experience in innovative drug development leads the research efforts. The goal is to create new and effective pain relief therapies.
- Jan 2025Seed$13.6M
#3
Series B · Nanjing, Jiangsu · founded 2015 · 46 employees$102.3Mraised▾
Provider of 3D printing pharmaceutical technology platform for drug design. The company focuses on the development of 3D bioprinters and Melt Extrusion Deposition (MED) 3D printing technology for dosage form design, and digital pharmaceutical product development.
- Sep 2023Series B$20.4M
- Jun 2021Series B$51M
- Dec 2020Series A$15.3M
- Jun 2018Series A$15.6M
#4
Public · Nanjing, Jiangsu · founded 2014 · 1576 employees$150.4Mraised▾
Developer of cell therapy to treat cancer and infectious diseases. The company focused on developing CAR-T cell therapies for hematologic malignancies, solid tumors, and infectious diseases.
- Apr 2023Post IPO$200M
- Mar 2020Series D$150.4M
#5
Series C · Nanjing, Jiangsu · founded 2017 · 400 employees$178Mraised▾
Provider of pharmaceuticals for cell therapies for oncology. Its technology involves CAR-T cell therapeutics for hematological malignant and its candidate like CT1038, RD102 and others.
- Jan 2023Series C—
- Sep 2021Series C$108M
- Mar 2020Series B$60M
#6
Series B · Nanjing, Jiangsu · founded 2017 · 90 employees$76.4Mraised▾
Developer of antibody-based therapeutics to treat various diseases. It offers BSI 045A drug candidate that targets IL4R immunizations for the treatments of asthma, atopic dermatitis, and others. Other products include BSI045B therapeutics for treating chronic obstructive pulmonary disease, BSI 038 drug candidate that targets CD40 for treating solid cancer, blood cancer, and many more.
- Apr 2023Series B—
- Dec 2022Series B$14.3M
- Dec 2021Series B$31.5M
- Dec 2020Series B$30.6M
#7
Series B · Nanjing, Jiangsu · founded 2018$15.5Mraised▾
Provider of therapeutics solution for the treatment of cancer and other rare diseases. The pipeline products of the companies are RC-01 (EGFR inhibitor) and RC-04 (ALK inhibitor) targeting non-small cell lung cancer. Other drug candidates of the companies are RC-06 and RC-08 targeting the solid tumor by tumor immunization and associated kinase.
- May 2023Series B—
- Jul 2021Series B$15.5M
#8
Public · Nanjing, Jiangsu · founded 2018 · 10 employees$81.9Mraised▾
Provider of humanized models and drug screening technologies. It offers research application for animal models for different drug and disease metabolism, functional analysis and evaluation, animal model like trasgenic mouse, ES gene editing and others. It also offers other technical services like cell-line, biological sample refrigeration and others.
- Sep 2020Series B$58.5M
- Jul 2019Series A$23.4M
#9
Series B · Nanjing, Jiangsu · founded 2011$15.8Mraised▾
Developer of medical imaging diagnostic devices. The company specializes in the research, development, and production of high-end medical equipment products. The product portfolio of the company inlcudes Surgical Fluorescence Imaging System, Endoscopic Fluorescence Imaging System, and Automatic digital pathological slice scanning and analysis system.
- Jan 2022Series B$15.8M
#10
Series B · Nanjing, Jiangsu · founded 2018 · 111 employees$18.8Mraised▾
Developer of medical devices for pulmonary diseases. The lead product INOwill is a portable NO generator that produces NO gas used for the treatment of pulmonary hypertension. Other products include NOVLIZ ureteral tube, NOTA prosthesis filling, INOcure NO gas therapy diabetic feet that provide antibacterial and antithrombotic functions.
- Nov 2021Series B$18.8M
#11
Public · Nanjing, Jiangsu · founded 2014$29.8Mraised▾
Nanjing Wei Li Zhi Bo Biotechnology is involved in research and development of a platform for tumor immunotherapy. The company has the intellectual property for single-target antibody and bispecific antibody for drug development technology platform. The leading candidates of the company anti-LAG3 and anti TIM3 are in the pre-clinical stage of a clinical study and the other candidates are in cell line stage of a clinical study and are effective against solid tumor.
- Oct 2020Series C$29.8M
#12
Series A · Nanjing, Jiangsu · founded 2017$10.3Mraised▾
Developer and provider of CAR T cell therapy-related technologies and services. The company has created a tumor cell-specific mutant protein library and provides screening of TIL cells targeting mutations to develop TIL cell therapy. Also provides CAR design services such as CAR virus packaging, CAR functional analysis, and CAR-T cell culture.
- Feb 2022Series A$10.3M
- Mar 2019Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Nanjing is moving
A read on the academic research around Biotechnology in Nanjing — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 318 papers.
- Nanjing Agricultural University117
- Nanjing Medical University58
- Nanjing University of Chinese Medicine40
- Nanjing Forestry University36
- Nanjing University36
- In vivo10
- Gene10
- Detection limit6
- Transcription factor6
- Cancer research5
- Gene knockdown1→7
- Resistance (ecology)1→4
- Long non-coding RNA1→3
- Antibiotics1→3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.